التفاصيل البيبلوغرافية
| العنوان: |
A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. |
| المؤلفون: |
Sigfridsson, Kalle, Nordmark, Anna, Theilig, Stefanie, Lindahl, Anders |
| المصدر: |
Drug Development & Industrial Pharmacy; Feb2011, Vol. 37 Issue 2, p185-192, 8p |
| مصطلحات موضوعية: |
DRUG absorption, SUSPENSIONS (Chemistry), SIZE reduction of materials, DRUG delivery systems, LABORATORY rats, DRUG development, PHARMACOKINETICS, NANOMEDICINE |
| مستخلص: |
Aim: The aim of this study was to maximize the exposure of a model compound (MC) for forthcoming high-dose toxicological studies with the physical form of the original compound unaffected. Method: The two evaluated formulation approaches for the present poorly water-soluble compound were micro- and nanosuspensions. Results: The particle size was about 280 nm for the nanosuspensions and about 4 μm for the microsuspensions. The crystallinity and the crystalline form of the ground samples were conserved. The physical and the chemical stabilities of the two kinds of suspensions were unaffected during the investigated time period. The in vivo results of the study showed that the pharmacokinetic parameters investigated were comparable at the low-dose level (6 μmol/kg) for both formulations after single administration. However, at the two higher doses (60 and 300 μmol/kg), a significant difference in exposure was observed between the two suspensions with an improved exposure for smaller particles. After Day 7 of repeated administration, a significant difference in exposure was observed at all dose levels. The overall exposures were higher on Day 7, compared to the exposures on Day 1 (most significant for nanoparticles), due to an accumulation of compound in the body. Conclusions: The nanoparticles have a larger surface, resulting in faster in vivo dissolution rate, faster absorption, and increased bioavailability, compared to microparticles. The differences in systemic exposure of model compound, following oral administration of nano- or microparticles of the drug substance, are probably caused by differences in the in vivo dissolution rate and possibly further enhanced by saturation of the systemic elimination. [ABSTRACT FROM AUTHOR] |
|
Copyright of Drug Development & Industrial Pharmacy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
